Indolent Systemic Mastocytosis — Trials

Indolent Systemic Mastocytosis — Trials · CancerIndex

Clinical trials

Registered studies

15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04910685	(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis	recruiting	Phase 2 / Phase 3	534	Blueprint Medicines CorporationINDUSTRY	23	Sep 23, 2026	clinicaltrials
NCT04333108	Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment	unknown	Phase 3	140	AB ScienceINDUSTRY	8	May 6, 2023	clinicaltrials
NCT00814073	Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis(AB06006)	completed	Phase 3	135	AB ScienceINDUSTRY	2	Dec 3, 2019	clinicaltrials

Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials